BOARD
Carl Stubbings
Independent Chair
BIO
Carl Stubbings
BAppS (Med Tech)
Carl is an experienced senior leader in the biotechnology and diagnostics industry with a focus on commercialisation, sales, marketing and business development.
He has considerable experience commercialising diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics (NASDAQ:DGX).
Since moving back to Australia Carl has held a number of executive roles including, Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC), CEO and Managing Director of Sienna Cancer Diagnostics Ltd (ASX: SDX), and Chief Operating Officer of BARD1(ASX:IIQ). More recently he was appointed Chief Commercial Officer of Genetic Technologies (ASX:GTG, NASDAQ :GENE). Carl has also assisted several Australian biotech companies with their commercialisation strategies, these companies include BCAL Diagnostics (ASX:BDX), Biotron (ASX: BIT) and Minomic International. He is also a Non-Executive Director of Sangui Bio, an unlisted private company.
Diana Nielson
Member Elected Director
BIO
Diana (Di) Nielson
BCom, Cert Nursing
Di is Head of Diagnostics at AstraZeneca ANZ and has over 35 years experience in healthcare and the pharmaceutical industry. For the last 8 years she has led the Diagnostics capability at AstraZeneca facilitating equitable and timely access to Genomics to support patient’s access to precision oncology. Di is passionate about the evolution and integration of genomics into routine healthcare.
She has strong relationships with an extensive network of National and International pathology and diagnostic providers regularly collaborating on key projects to enhance access to genomics for Australians.
Di has extensive commercial experience and currently sits on the Oncology Leadership Team at AstraZeneca. Prior to this she worked across the pharmaceutical industry in a variety of roles supporting the commercialisation of Precision Oncology medicines and identification of the associated biomarkers.
Mark Grosser
Member Elected Director
BIO
Mark Grosser
BEng, BBus
Mark is the co-founder and CEO of 23 Strands Pty Ltd (23Strands), and is utilising whole genome sequencing and Artificial Intelligence to unlock the power of patient’s genetic code to provide a more accurate pathway to better patient outcomes.
23Strands is currently commercialising genomics screening and diagnostics across Women’s and reproductive health and is a key industry partner in over $30 million of translational and AI based grants and initiatives.
Mark is an experienced Engineer and business manager with over 20 years’ experience in the health technology industry where he has worked at companies such as Cochlear, Micromedical, Ventracore and the Henry Schein Group. He has significant track record in the commercialization of health innovations across a range of diagnostic, pharmaceutical and device markets.
He also is a passionate advocate for early stage innovation in Australia and has been an active mentor and supporter to the start up ecosystems across health, biological sciences and financial innovation. He currently is a member of several successful businesses and not for profits and sits on an Early Stage Venture Capital Investment Committee.
Edith Hurt
Independent Director
BIO
Edith Hurt
MHumanServ (Mgt&Policy), MDataScience (Strat&Lship), RN, GAICD.
Edith Hurt is an experienced Senior Executive, Company Secretary and
Company Director with extensive leadership experience in health, medical
research and for purpose organisations.
Her work in public health commenced as a Registered Nurse and includes roles
with beyondblue, and in medical research as Operations Manager of the ProCan
multi-omic program at the Children’s Medical Research Institute at Westmead.
She has an understanding of the Australian health system, including clinical
aspects, research, clinical trials and commercialisation and an appreciation of
where genomics does and could impact, along with the challenges and potential
barriers to adoption.
Edith was the inaugural Company Secretary and founding board member of the
Can Too Foundation and Chair of the Research Investment Committee. She
has over 10 years of commercial and not-for-profit Non-Executive Director
experience in health, community and business sectors.
Her background in management consulting provides a broad base of strategic
and operational knowledge, used to providing organisational advice, guidance
and insights to Executive Leaders on strategic direction, operational delivery,
risk management and governance.
A master’s degree in Human Services (Management and Policy), and experience
in Government Relations and Advocacy in not-for-profit organisations has given
Edith experience in industry, peak bodies, partner organisations and
government working groups developing policy. As a senior digital health leader,
with a Master of Data Science (Strategy & Leadership) and significant complex
program management experience, she has overseen the delivery of multiple
concurrent multi-omic research studies and has a track record of fostering
positive working relationships with key stakeholders in industry and
government to enhance an organisation’s reputation and impact.
Oliver Bonaccorso
Member Elected Director
BIO
Oliver brings 17 years of experience in the genomics industry, showcasing a diverse background that spans commercial and strategic roles across the life sciences, diagnostics, and pharmaceutical sectors. Currently, he serves as the Precision Medicine and Diagnostics Lead at Johnson & Johnson (J&J), where he leverages his extensive network of contacts within the diagnostic pathology industry and technology manufacturers to ensure high quality testing is available to patients. Within J&J, he manages the diagnostic strategy across all therapeutic areas.
Oliver has a keen interest in regulatory policy and reimbursement frameworks for companion diagnostics. He believes that prompt and equitable access to funded testing is crucial for the successful implementation of precision medicine.
He is passionate about the implementation of cutting-edge genomic technologies into clinical practice to improve diagnostic yield while minimizing costs and accelerating time to results for patients.
Gretchen Weightman
Member Elected Director
BIO
Gretchen Weightman
Vice President & General Manager, Asia Pacific, Oxford Nanopore Technologies
Gretchen is Vice President and General Manager, Asia Pacific, at Oxford Nanopore Technologies. In this role, she is responsible for shaping the company’s commercial strategy and driving growth across one of the most dynamic and diverse regions in the world—including China, Japan, South Korea, Australia, Singapore, and beyond.
A passionate and values-led leader, Gretchen is known for building high-performing, purposedriven teams that deliver meaningful impact. She brings over 25 years of experience across genomics, diagnostics, and healthcare systems, and has worked alongside researchers, clinicians, industry disruptors, governments, and patient advocates to drive innovation, expand access, and foster equity across Asia, the Middle East, and Africa.
At Oxford Nanopore, she is inspired by the power of real-time, information-rich sequencing technology to transform how we understand and apply biology. By enabling scientists and clinicians to explore the genome, epigenome, transcriptome, and proteome in their most native states, Oxford Nanopore is not only advancing multi-omics discovery but also accelerating clinical delivery. These insights are redefining what’s possible—from improving population health and enabling earlier disease detection, to enhancing biosecurity and driving climate resilience.
Previously, Gretchen held senior leadership roles at Illumina, where she played a pivotal role in expanding access to genomics across emerging markets and accelerating innovation with a focus on equity and sustainability. She brings a strong track record of navigating complex, multinational environments and scaling businesses for long-term impact.
Above all, Gretchen is passionate about leading with authenticity and purpose. As a proud mum to two daughters, she is committed to showing them—and future generations—that passion, impact, and leadership can thrive together.
David Atkins, PHD
Independent Director
BIO
David Atkins, PhD
CEO, Rhythm Biosciences
Dr Atkins has over 30 years’ experience as a global leader in a broad range of life science and healthcare businesses with a significant focus on diagnostic products and services. He has held senior leadership positions in R&D, business development, operations and sales and marketing. David has extensive commercial experience in North America, EMEA, Asia and Latin America.
Dr Atkins is currently CEO of Rhythm Biosciences (ASX:RHY) an ASX-listed cancer diagnostics business. Prior to this he was CEO of Congenica located in Cambridge UK and successfully led the business through a major transformation, several rounds of fund raising and established Congenica as a global leader in the use of genomic data to diagnose rare disease and inherited cancers. Prior to joining Congenica, Dr Atkins has over 20 years’ experience with Johnson & Johnson based in Australia, US, Canada, and UK in a broad range of roles including R&D, business development and in global commercial roles. In addition, he was CEO of Synevo, a clinical diagnostic laboratory service business operating across Germany and Eastern Europe and global head of the Advanced Staining pathology business unit for Leica Biosystems, a Danaher Company. David previously was an active scientist with over 30 peer-reviewed publications.
David is also currently and Entrepreneur-in-Residence at both UNSW, Sydney and the Wellcome Sanger Institute in Cambridge, UK. He also chairs the investment committee of BioNSW.